myoclonus from antibiotic therapy (ceftazidime-induced neurotoxicity): a case study and review
Clicks: 240
ID: 155314
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
240 views
21 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #25 of 52 articles by views in translational behavioral medicine
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
A 78-year-old Chinese man with a history of end stage renal
disease (ESRD) presented with fever of one day duration. He
was treated for catheter related sepsis with intravenous
piperacillin and tazobactam, which was later switched to
vancomycin and ceftazidime secondary to persistent fever
with negative cultures. One the fifth day of treatment with
vancomycin and ceftazidime, he developed new onset
upper limb myoclonus which progressed to bilateral upper
limb ataxia. A provisional diagnosis of myoclonus and ataxia
secondary to neurotoxicity related to ceftazidime was made
and the ceftazidime was ceased. His symptoms resolved
over three days and he returned to his baseline neurological
status by Day 5 following cessation.
| Reference Key |
ong2017australasianmyoclonus
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Chong Yau Ong;Yan Qin |
| Journal | translational behavioral medicine |
| Year | 2017 |
| DOI |
10.21767/AMJ.2017.3136
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.